Cell division cyclin 25C knockdown inhibits hepatocellular carcinoma development by inducing endoplasmic reticulum stress

BACKGROUND Cell division cyclin 25C(CDC25C)is a protein that plays a critical role in the cell cycle,specifically in the transition from the G2 phase to the M phase.Recent research has shown that CDC25C could be a potential therapeutic target for cancers,particularly for hepatocellular carcinoma(HCC).However,the specific regulatory mechanisms underlying the role of CDC25C in HCC tumorigenesis and development remain incompletely understood.AIM To explore the impact of CDC25C on cell proliferation and apoptosis,as well as its regulatory mechanisms in HCC development.METHODS Hepa1-6 and B16 cells were transduced with a lentiviral vector containing shRNA interference sequences(LV-CDC25C shRNA)to knock down CDC25C.Subsequently,a xenograft mouse model was established by subcutaneously injecting transduced Hepa1-6 cells into C57BL/6 mice to assess the effects of CDC25C knockdown on HCC development in vivo.Cell proliferation and migration were evaluated using a Cell Counting Kit-8 cell proliferation assays and wound healing assays,respectively.The expression of endoplasmic reticulum(ER)stress-related molecules(glucose-regulated protein 78,X-box binding protein-1,and C/EBP homologous protein)was measured in both cells and subcutaneous xenografts using quantitative real-time PCR(qRT-PCR)and western blotting.Additionally,apoptosis was investigated using flow cytometry,qRT-PCR,and western blotting.RESULTS CDC25C was stably suppressed in Hepa1-6 and B16 cells through LV-CDC25C shRNA transduction.A xenograft model with CDC25C knockdown was successfully established and that downregulation of CDC25C expression significantly inhibited HCC growth in mice.CDC25C knockdown not only inhibited cell proliferation and migration but also significantly increased the ER stress response,ultimately promoting ER stress-induced apoptosis in HCC cells.CONCLUSION The regulatory mechanism of CDC25C in HCC development may involve the activation of ER stress and the ER stress-induced apoptosis signaling pathway.

Regulation of mitochondrial carrier SLC25A13 on breast cancer cell cycle in vitro

Objective·To investigate the role of mitochondrial solute carrier family 25 member 13(SLC25A13)on breast cancer development.Methods·SLC25A13 mRNA and protein expressions in invasive breast cancer tissues and normal breast tissues were from The Cancer Genome Atlas(TCGA)breast cancer dataset.Survival analysis was conducted online by Kaplan-Meier software.MCF-7 cell line was used for in vitro cell assay.Knockdown of SLC25A13 and sirtuin 2(SIRT2)were conducted by siRNA transfection.Cell viability was measured with trypan blue exclusion.Cell cycle arrest was determined by flow cytometry.The mRNA expression of SLC25A13 and P27 were detected by quantitative PCR.The protein level of SLC25A13,P27 and SIRT2 were detected by Western blotting.Protein half-life of P27 was assessed by Western blotting after cycloheximide treatment.Results·SLC25A13 was up-regulated in invasive breast cancer tissues.High expression of SLC25A13 correlated with poor overall survival and breast cancer recurrence.SLC25A13 knockdown inhibited MCF-7 cell cycle progression.P27 and SIRT2 both accumulated after SLC25A13 knockdown.P27 accumulation resulted from prolonged protein half-life.Knockdown of SIRT2 restored cell cycle arrest as well as P27 accumulation caused by SLC25A13 silencing.Conclusion·High expression of SLC25A13 may promote cell cycle progression via SIRT2 in breast cancer development.

Influence of FSH Treatment on Expression of CDC25A, TSSK3 and P53 in Vitro Cultured Sertoli Cells of Calf

CDC25A, TSSK3 and P53 expressions in vitro in cultured sertoli cells after FSH treatment were studied in order to provide some data for further researches of spermatogenesis. Different concentrations of FSH（0, 0.01, 0.02, 0.04, and 0.08 IU ·m L^-1） were used to treat sertoli cells cultured in vitro. The expression of CDC25 A, TSSK3 and P53 was determined by real-time-PCR at 6 h,12 h and 24 h after FSH treatment of sertoli cells. The results showed that FSH had no significant effect on expression of CDC25A（p〈0.05）, could significantly improve the expression of TSSK3 and P53（p0.05）, and had no significant effect on expression of CDC25 A in sertoli cells, but it could significantly improve the expression of TSSK3. CDC25 A was likely to play a role in other signaling pathways in sertoli cells. Within the range of certain concentration of FSH, TSSK3 in sertoli cells had the highest expression at about 24 h. TSSK3 protein produced in sertoli cells was likely to play an important role in substrate-level phosphorylationbe in meiosis and mitosis of spermatogenic cells. FSH could promote P53 expression and the highest expression was at about 12 h, and P53 might control the division of spermatogenic cells as well as sertoli cells.

Expression and interaction of CDC25A and IL-6 in hepatocellular carcinoma HepG2 cells

Objective:This study was to further investigate the effect of CDC25A gene on proliferation, invasion and metastasis of hepatocellular carcinoma HepG2 cells, and to explore whether CDC25A and IL6 interact in liver cancer.Methods: HepG2 cells were transfected with lentiviral CDC25A-shRNA to specifically block the expression of CDC25A in the experimental group (KD group), transfected with lentiviral-negative shRNA as a negative control group (NC group), and the conventionally cultured HepG2 cells were blank control group (Control group). Real-time quantitative PCR and Western blot were used to detect the mRNA and protein expression levels of CDC25A and IL6.Results:The expression level of IL6 mRNA in the experimental group was 0.4650.026, which was significantly lower than that of the negative control group of 1.0940.179 and the blank control group of 1.0020.311. The difference was statistically significant(P<0.05). The protein expression level of IL6 was 0.4990.061, which was significantly lower than the negative control group of 1.3110.034 and the blank control group of 1.2530.035. The difference was statistically significant (P<0.05). Conclusions: The CDC25A gene in hepatoma HepG2 cells was silenced, while the expression of IL6 was down-regulated. CDC25A may play a role in the development and invasion of liver cancer by regulating the expression of IL6.

乳腺癌中CDC25A和P57^(kip2)蛋白表达与病理分级及临床分期的关系

目的探讨CDC25A和P57^(kip2)蛋白在乳腺癌中的表达与病理分级、临床分期的关系,并对CDC25A和P57^(kip2)之间的相关性进行研究。方法选择免疫印迹方法对64例乳腺癌患者进行检测,对CDC25A和P57^(kip2)蛋白在乳腺癌中的表达、病理特征以及临床分期三者之间的联系进行确切的研究探讨。结果乳腺癌以及癌细胞周围的正常细胞中都能够找CDC25A蛋白的表达,但在乳腺癌中则表现为高密度表达(P<0.05);肿瘤的分化程度越低,CDC25A蛋白的表达逐渐提升(P<0.05)。CDC25A蛋白表达在临床Ⅰ期、Ⅱ期,是否伴有淋巴结转移间比较,差异有统计学意义(P<0.05)。P57^(kip2)蛋白在乳腺癌中呈低水平表达,在癌旁正常腺体中均呈高表达(P<0.05),但在伴和不伴淋巴结转移中差异无统计学意义(P>0.05)。结论 CDC25A的过度表达和P57^(kip2)的低表达可能在乳腺癌的发生中起作用;乳腺癌发生机制中有涉及细胞周期调节环路中的CDC25A、P57^(kip2)基因的异常;CDC25A及P57^(kip2)可能成为乳腺癌的诊断标记,预后判断。

Discovery of a potent and selective cell division cycle 7 inhibitor from 6-(3-fluoropyridin4-yl)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as an orally active antitumor agent

To the Editor:Kinase cell division cycle 7(CDC7),a cell division cycle protein,takes a vital role in mediating DNA replication1.CDC7 complexes in the nucleus can phosphorylate the minichromosome maintenance complex(MCM)family members that bind to chromosomes.In addition,CDC7 kinase,as a molecular switch regulating DNA replication,can mediate DNA damage signaling pathways to stimulate cell cycle termination as well as DNA replication2.Studies have shown that CDC7 is overexpressed in many types of cancer cells,and its overexpression was related to poor patient survival,tumor grade,genetic instability,aneuploidy and so on3.Therefore,CDC7 is a promising target for antitumor therapy.

p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy

AIM： Esophageal squamous cell carcinoma is generally sensitive to chemoradiotherapy （CRT）, but some cases are not. Using a retrospective analysis, we aimed to identify the predictors of the response by esophageal squamous cell carcinoma to definitive CRT. METHODS： The intensities of expression of p53, Ki67, Bci-2, Bax, olclin D1, VEGF, CDC25B, and metallothionein （MT） were evaluated immunohistochemically in the biopsy specimens obtained before CRT, and the intensities of their expression were tested for correlations with the clinical effects of CRT. RESULTS： The esophageal squamous cell carcinomas with negative p53, positive CDC25B, and negative MT expression were found to be significantly more sensitive to CRT. In addition, p53 positivity and CDC25B positivity respomd well to CRT. CONCLUSION： Esophageal squamous cell carcinomas with negative p53,positive CDC25B, and negative MT expressions respond well to CRT. Even with p53 positivity, if with CDC25B positivity, CRT can be expected. 2005 The WJG Press and Elsevier Inc. All rights reserved

Expression of CDC42 in cervical squamous cell carcinoma and its correlation with clinicopathologic characteristics

Objective： The high expression of cell division cycle 42 protein （CDC42） may be involved in the occurrence and progression of several tumors. However, the expression and function of CDC42 in cervical squamous cell carcinoma remains unclear. This study aimed to investigate the expression of CDC42 in cervical squamous cell carcinoma and its correlation with clinicopathologic characteristics. Methods： The expression of CDC42 in 162 cervical squamous cell carcinoma tissue samples and 33 normal cervical tissue samples was investigated by immunohistochemistry. The CDC42 mRNA expression was detected by reverse transcription-polymerase chain reaction （RT-PCR）. Results： The cervical squamous cell carcinoma group showed a significantly higher CDC42 positive rate, compared to the normal cervical tissues （P〈0.05）. Fttrthermore, the tissues of stage Ⅱ-Ⅳ carcinoma patients showed higher CDC42 expression levels compared to stage I patients （P=0.05）. In addition, the expression of CDC42 was not correlated to age of patients, differentiation degree of cancer cells, or lymph node metastasis （P〉0.05）. Furthermore, compare with normal cervical tissues, the CDC42 mRNA expression in cervical cancer had no significant difference. Conclusions： CDC42 was up-regulated at protein level, but not mRNA level, in cervical squamous cell carcinoma. The high expression of CDC42 was correlated to the clinical stage of the patients, indicating that CDC42 might contribute to the progression of cervical squamous cell carcinoma.

Anti-hepatoma Effect of DC2.4 Cells Transfected with Tumor-Associated Antigen Cdc25C In Vitro

Objective Cell division cyclin 25 homolog C(Cdc25C)is a tumor-associated antigen candidate gene,and this may be used as an effective target in cancer treatment.The present study aims to evaluate the lysis effect of cytotoxic T lymphocytes(CTLs)induced by dendritic cell line DC2.4 overexpressing Cdc25C,and the feasibility of Cdc25C as a component in hepatoma immunotherapy.Methods The mouse Cdc25C gene was ligated into a lentiviral vector,and transfected into DC2.4 cells.The DC2.4 cell phenotype and cytokine secretion were determined by flow cytometry and ELISA,respectively.CD8^(+)T cells were sorted from the spleens of C57BL/6 mice using a magnetic bead sorting kit obtained from Miltenyi Biotech,Germany,and co-cultured with DC2.4 cells for one week as effector cells.Then,IL-2,granzyme B and perforin were detected in the CTL culture medium by ELISA.Next,time-resolved fluorescence immunoassay was used to detect the immune killing effect of Cdc25C-specific CTLs on target cells.Meanwhile,the effect of blocking MHC-I sites on target cells with a monoclonal anti-MHC-I antibody was evaluated.Results The results revealed that Cdc25C could be stably overexpressed in DC2.4 cells by LV-Cdc25C infection.DC2.4 cells transfected with LV-Cdc25C secreted more IL-6,IL-12,TNF-αand IFN-γ,and had higher expression levels of CD40,CD86,CCR7 and MHC-II than unaltered DC2.4 cells.The elevated Cdc25C in dendritic cells also further increased the secretion of IL-2,granzyme B and perforin to elicit Cdc25C-specific CTLs,and induced the higher cytotoxicity in Hepa1-6 cell lines(P<0.05),but this had no effect on the target cells when MHC-I monoclonal antibodies were blocked.Conclusion DC2.4 cells transfected with LV-Cdc25C can induce specific CTLs,and result in a strong cellular immune response.The dendritic cells that overexpress Cdc25C may be useful for hepatoma immunotherapy.

Dysregulation of the TGF-β Postreceptor Signaling Pathway in Cell Lines Derived from Primary or Metastatic Ovarian Cancer

Transforming growth factor beta (TGF β) may cause cell cycle arrest, terminal differentiation, or apoptosis in most normal epithelial cells, whereas most malignant cell lines are resistant to TGF β. Mechanisms of resistance to TGF β caused by modulation of cell cycle regulators and/or inactivation of components of the TGF β signaling transduction pathway such as C myc and Smad4 are not well understood. To investigate the potential association between loss of sensitivity to TGF β and expression status of transforming growth factor receptor Ⅱ (TβRⅡ), Smad4, CDC25A and C myc in 14 cell lines derived from ovarian cancer, the expression levels of these genes were detected by semi quantitative RT PCR. Normal ovarian surface tissues were used as controls. The expression of TβRⅡ was detectable in all of 14 cell lines. The expression of Smad4 was decreased in 10 cell lines and 9 cell lines overexpressed CDC25A, as compared to normal controls. CDC25A gene was overexpressed with 88 % (8/9) in tumorigenic cell lines as determined by xenografts in nude mice, and only in 20 % (1/5) of non tumorigenic cell lines ( P <0.05). C myc was not overexpressed in any of these cell lines. The loss of sensitivity to TGF β of cell lines derived from ovarian cancers may be related to a decreased expression of Smad4, which mediates TGF β induced growth inhibition, and/or an overexpression of CDC25A. This overexpression of CDC25A correlates with increased tumorigenicity of ovarian cancer cell lines. The loss of sensitivity to TGF β is not associated with a lack of TβRⅡ.

CDC25B Involved in Proliferation of Sertoli Cells of New Born Calves Through FSH and Possibly Being Key Regulating Factor

The effects of FSH on the proliferation of sertoli cells of new born calves were studied in order to provide some data for theoretical research and practical use of spermatogenesis in vitro. Different concentrations of FSH （0, 0.01, 0.02, 0.04, and 0.08 IU· mL^-1） were taken to treat bovine sertoli cells in vitro culture, the number of sertoli cells and the expression of seven genes were determined at 6, 12 and 24 h after FSH treatments. FSH could significantly promote the proliferation of in vitro cultured sertoli cells. FSH had no significant effects on the expression of CDC25A and could significantly improve the expression of CDC25B. 0.04 IU· mL^-1 and 0.08 IU· mL^-1 FSH treatments decreased the expression of CDC25C at 12 h. 0.08 IU· mL^-1 FSH treatment decreased the expression of CDC25C at 24 h. 0.04 IU. mLI FSH could significantly decrease the expression of GSK-3β and improve the expression of β-catenin at 6, 12 and 24 h. 0.02, 0.04 and 0.08 IU· mL^-1 FSH treatments enhanced the expressions of CYCLIND1 and C-MYC. In conclusion, FSH promoted the proliferation of sertoli cells and 0.04 IU· mL^-1 FSH concentration could significantly promote the proliferation of in vitro cultured sertoli cells. FSH promoted the proliferation of sertoli cells by CDC25B and WNT/ β-eatenin and CDC25B might be the key regulator to the proliferating rate of sertoli cells of bovine calf.

FSH Promoting Proliferation of Calf Sertoli Cells Through Wnt/β-catenin Signaling Pathway with CDC25B Being Involved

The aim of this experiment was to investigate whether FSH could regulate the proliferation of calf Sertoli cells and the relationship with CDC25 B through Wnt/β-catenin signaling pathway. The experimental method was to culture Sertoli cells with different concentrations of FSH(40, 80, 120 and 150 ng · mL) and to treat the cultured cells with XAV939(β-catenin inhibitor) and to detect the expression of CDC25 B, CDC2, C-MYC and β-catenin. The results of the experiment showed that FSH could promote the proliferation of cells and its effect was good at 80 ng · mLconcentration. FSH could promote the expression of CDC25 B, CDC2, C-MYC and β-catenin. The expression of C-MYC and β-catenin in group FSH+XAV939 was lower than that in group FSH. There was no difference in mRNA expression of CDC25 B in group FSH and group FSH+XAV939. The protein expression of CDC25 B in group FSH+XAV939 was lower than that in group FSH. The conclusion was that FSH could promote the proliferation of calf Sertoli cells through Wnt/β-catenin signaling pathway. CDC25 B was upregulated by FSH and CDC2 could promote the proliferation of calf Sertoli cells. The protein level of CDC25 B was affected by Wnt/β-catenin signaling pathway.

细胞分裂周期蛋白73基因缺失抑制粟酒裂殖酵母细胞的有性生殖和有丝分裂

cdc73基因编码粟酒裂殖酵母(Schizosaccharomyces Pombe)RNA聚合酶Ⅱ辅助因子Cdc73,参与G_(2)期检查点激活并调控细胞周期。但cdc73基因缺失对细胞有丝分裂动力学的调控尚不清楚。本研究采用活细胞成像、荧光蛋白标记技术探究粟酒裂殖酵母cdc73基因缺失后对细胞有性生殖和细胞有丝分裂中微管、肌动蛋白、线粒体和组蛋白动力学的影响。结果表明:在有性生殖中,cdc73基因缺失会导致子囊孢子长度增加14.23%,产4个孢子数量的细胞减少64.08%;活细胞成像结果分析发现,在有丝分裂中,分裂后期微管伸长的长度缩短11.21%,伸长时间减少17.39%;肌动蛋白环形成和收缩速率分别降低33.33%和26.09%,形成和收缩时间分别延长58.00%和40.38%;同时,肌动蛋白环、线粒体和组蛋白表达量都增加。本研究揭示了cdc73基因缺失可抑制有丝分裂中纺锤体的伸长,延缓肌动蛋白环的形成与收缩,为进一步探寻Cdc73蛋白在细胞分裂中参与调控微管和肌动蛋白动力学功能提供了一定的科学依据。

新型细胞分裂周期25磷酸酯酶B和蛋白酪氨酸磷酸酶1B抑制剂三唑并噻二唑-均三嗪的合成

以苯亚氨基为桥,设计合成了18个含有三唑并噻二唑和均三嗪双杂环的新型分子(4a^4i和5a^5i),并利用红外光谱、核磁共振谱和高分辨质谱等技术手段对其进行了结构表征。将吗啉和四氢吡咯分别与三聚氯氰发生双取代反应合成三嗪衍生物(1A和1B),然后将1A和1B分别与对氨基苯甲酸反应,合成重要中间体(2A和2B)。通过熔融法将8种脂肪酸与二氨基硫脲缩合得1,2,4-三唑衍生物3a^3h,最后将2A和2B在三氯氧磷和四丁基溴化铵催化下分别与3a^3h反应得目标产物。为了进一步比较3-脂肪基和3-苯基对药效活性的影响,利用相同方法设计合成了目标产物4i和5i。评价了目标产物对细胞分裂周期25磷酸酯酶B(Cdc25B)和蛋白酪氨酸磷酸酶1B(PTP1B)抑制活性。结果发现:所有目标分子对Cdc25B均表现出良好的抑制活性,半抑制浓度(IC_(50)值)在2.40~0.31 mg/L之间,目标分子4a^4f和5a^5i的IC_(50)值均低于阳性参照物Na_3VO_4[(1.25±0.14)mg/L],有望成为潜在的Cdc25B抑制剂;在PTP1B测试中,14个目标分子具有优良的抑制活性,IC_(50)值在0.98~0.37 mg/L之间,低于阳性参照物齐墩果酸[(1.19±0.27)mg/L],有望成为潜在的PTP1B抑制剂。

姜黄素对β-淀粉样肽(25-35)诱导去血清培养PC12细胞周期异常与细胞凋亡的影响

目的:探讨姜黄素(Cur)对β-淀粉样肽(25-35)(βamyloid peptide-25-35,Aβ25-35)诱导体外去血清培养的PC12细胞周期异常与凋亡的影响。方法:PC12细胞用常用的去血清培养使细胞同步于G0期,用MTT比色法分析细胞存活率,流式细胞仪检测分析细胞周期与凋亡,Hoechst33258荧光染色观察细胞核凋亡的形态学改变,RT-PCR和Western blot从mRNA及蛋白水平检测p21基因的变化。结果:用不同终浓度(0,1.25,2.5,5,10,20μmol.L-1)Cur预处理去血清培养的PC12细胞1 h,再用Aβ25-35处理24 h,细胞存活率增加;Aβ25-35引起的S期细胞百分率明显减少,凋亡率明显降低(P<0.01),亚二倍体峰消失;核固缩、碎裂减少;p21 mRNA表达和P21蛋白表达增加。结论:Cur可以影响Aβ诱导的去血清培养PC12细胞周期分布及减少凋亡,可能与上调p21的表达有关。

Micro RNA-106b-25簇与肿瘤

Micro RNA(miRNA)是一种由染色体内含子部分编码的,通过降解靶基因的mRNA或抑制其翻译来调控基因表达的小RNA分子,其功能涉及众多的生物学进程,包括增殖、凋亡、发育以及分化等,miRNA的异常表达更是与许多疾病的发生发展相关,如血液肿瘤及实体瘤。miR-106b-25簇micro RNA包括miR-106b、miR-93和miR-25,这些miRNA的功能涉及了肿瘤发生发展等诸多生物进程。该文将就miR-106b-25簇对肿瘤的影响做一综述。

1α,25(OH)_2D_3通过阻滞细胞周期抑制胃癌细胞系增殖

目的研究1α,25(OH)2D3对胃癌细胞增殖和细胞周期的影响,并探讨其相关的作用机制。方法 BGC-823和SGC-7901胃癌细胞系分别给予终浓度为1×10-10～1×10-7mol/L的1α,25(OH)2D3处理72 h,用MTT法检测细胞抑制率;用流式细胞仪检测细胞周期;用RT-qPCR技术检测细胞周期相关基因P21、cyclin D1、cyclin E1和CDK6 mRNA表达。结果 1α,25(OH)2D3对胃癌细胞的增殖抑制率具有浓度依赖性,1α,25(OH)2D3干预导致BGC-823和SGC-7901细胞系G1期细胞比例升高,S期细胞比例降低(P<0.05);1α,25(OH)2D3干预后,BGC-823和SGC-7901胃癌细胞P21 mRNA表达升高(P<0.01),而cyclin D1、cyclin E1和CDK6 mRNA表达降低(P<0.01)。结论 1α,25(OH)2D3抑制胃癌细胞增殖,诱导细胞周期阻滞,可能与上调P21,下调cyclin D1、cyclin E1和CDK6的表达有关。

1α,25-二羟基维生素D3通过表皮生长因子受体和细胞周期调节卵巢癌细胞的生长

目的:研究1α,25-二羟基维生素D3(1,25VD3)通过对表皮生长因子受体和细胞周期的调控调节人卵巢癌细胞的生长。方法:用1,25VD3处理人卵巢癌细胞株OVCAR3后,MTT法测定细胞生长情况,流式细胞仪分析细胞周期,Western blot检测EGFR表达。用pcDNA3-EGFRvIII质粒转染OVCAR3细胞,筛选出稳定过表达EGFR的克隆株EGFR-OVCAR3。用1,25VD3及EGFR抑制剂分别处理OVCAR3和EGFR-OVCAR3细胞,Western blot检测p27、Cyclin E和GADD45蛋白表达。结果:1,25VD3下调OVCAR3细胞EG-FR蛋白表达,对细胞生长有明显抑制作用,使其G0/G1和G2/M期增多,S期明显减少,而对EGFR-OVCAR3细胞无明显作用。Western blot显示,1,25VD3上调OVCAR3细胞p27和GADD45蛋白表达,下调Cyclin E蛋白表达,而对EGFR-OVCAR3细胞三种蛋白表达无调节作用,用EGFR抑制剂处理EGFR-OVCAR3细胞后,又能调节p27和cyclin E蛋白的表达。结论:1,25VD3可以调节EGFR蛋白表达,并进而调节下游分子,包括p27和GADD45,最后调控细胞周期,抑制细胞G1/S期转换和G2/M期转换,从而抑制卵巢癌细胞的生长。

地塞米松和1,25-(OH)_2D_3对EC1细胞增殖和细胞周期的影响

目的:观察地塞米松(DEX)和1,25-(OH)2D3及2药联用对食管鳞状细胞癌EC1细胞增殖及周期的影响。方法:分别用10-7mol/LDEX与10-7mol/L1,25-(OH)2D3以及同种浓度2药联合处理EC1细胞48、72和96h,并设溶剂对照组。采用MTT法检测细胞增殖情况及流式细胞仪检测细胞周期变化。结果:1,25-(OH)2D3单独应用具有抑制EC1细胞增殖的作用(F1,25-(OH)2D3=51.185,P<0.001);DEX单独应用具有阻滞细胞周期的作用(FDEX=8.170,P=0.009)。DEX、1,25-(OH)2D3及时间3种因素两两间均存在交互作用(细胞增殖抑制:F1,25-(OH)2D3×DEX=11.017,P=0.003;F1,25-(OH)2D3×时间=3.668,P=0.041;FDEX×时间=7.887,P=0.002。G0/G1期细胞比率:F1,25-(OH)2D3×DEX=12.381,P=0.002;F1,25-(OH)2D3×时间=6.583,P=0.005;FDEX×时间=5.096,P=0.014),且两药间提示存在拮抗作用。未发现3因素之间存在交互作用(细胞增殖抑制:F1,25-(OH)2D3×DEX×时间=0.512,P=0.606。G0/G1期细胞比率:F1,25-(OH)2D3×DEX×时间=0.410,P=0.668)。结论:DEX和1,25-(OH)2D3单独及联合使用能对EC1细胞增殖起抑制作用,且使EC1细胞周期阻滞在G0/G1期。

CDC25B在大肠癌中的表达及意义

目的检测细胞分裂周期蛋白25B(CDC25B)在正常大肠组织、大肠增生性息肉、大肠腺瘤及大肠癌组织中的表达,探讨其是否可以作为大肠癌早期诊断的分子标志物。方法采用免疫组化染色(SP法)技术检测50例大肠癌组织、30例大肠腺瘤组织、10例大肠增生性息肉组织、10例正常大肠组织中CDC25B的表达。结果 CDC25B在在正常大肠、大肠增生性息肉、大肠腺瘤及大肠癌组织中的表达率分别为0、0、53.33%和76.00%,与大肠癌组织比较差异均有统计学意义(P<0.05)。CDC25B的表达与血清CEA有相关性(P<0.05),而与大肠癌患者的发病年龄、性别、民族、肿瘤大小、临床分期、有无淋巴结转移、组织学分级、血清CA-199及远处转移无相关性(P>0.05)。结论 CDC25B在大肠腺瘤及大肠癌中高表达,其可能参与了大肠腺瘤到大肠癌的转变过程;CDC25B在大肠癌组织的表达与大肠癌患者血清CEA有关,表明CDC25B表达可能参与了大肠癌发生发展,在大肠癌的进展中起一定的作用。